This study is looking at a combination of two drugs, Inavolisib and Fulvestrant, for people with locally advanced (cancer that has spread to nearby tissues) or metastatic (cancer that has spread to other parts of the body) breast cancer. Specifically, it's for those whose cancer is hormone receptor-positive (ER+), HER2-negative, and has a specific genetic change called PIK3CA mutation. You would have already received a type of treatment called a CDK4/6 inhibitor. The study aims to see how well this drug combination shrinks tumors and if it causes any side effects. We are looking for about 80 participants, aged 18 and older, of all genders. Your tumor must be ER+/HER2- and have the PIK3CA mutation to be eligible.

Study design

This interventional study plans to enroll 80 participants. The specific phase of the study is not mentioned.

What's involved

Participants will receive Inavolisib and Fulvestrant according to a schedule. The record does not specify the number of visits or other procedures.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for up to approximately 2 years to measure tumor response and side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.